AI assistant
Sending…
Immuneering Corp — Director's Dealing 2025
Sep 30, 2025
32973_dirs_2025-09-30_1960c096-0dd8-4510-ab7a-56751646f321.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-09-29
Reporting Person: Feinberg Peter (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-29 | Class A Common Stock | P | 5000 | $7.18 | Acquired | 141766 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 392242 | Indirect |
| Class A Common Stock | 476615 | Indirect |
| Class A Common Stock | 115441 | Indirect |
More from Immuneering Corp
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Major Shareholding Notification
2026
Jan 22